美国、瑞典和以色列2型糖尿病的药物治疗
研究比较了2007至2018年美国NHANES、瑞典SCREAM和以色列Maccabi数据库中2型糖尿病患者的降糖药物使用情况。2017-2018年,NHANES和SCREAM的降糖药使用率(66.0%、68.4%)低于Maccabi(88.1%),二甲双胍使用率也较低,而磺脲类使用率在NHANES较高。SGLT2i和GLP1RA在高危患者中的使用有限,且与合并症无一致关联。
要点
- 2017-2018年降糖药使用率:NHANES 66.0%,SCREAM 68.4%,Maccabi 88.1%。
- 二甲双胍使用率:NHANES 74.1%,SCREAM 75.9%,Maccabi 92.6%。
- 磺脲类使用率:NHANES 31.5%,SCREAM 16.0%,Maccabi 14.9%。
核心结论
- 美国、瑞典和以色列在2型糖尿病降糖药物真实世界使用上存在显著差异,以色列的药理管理更优。
- 各国医疗可及性和药物成本的差异可能导致了这些差异。
- 在此期间,三个国家高危患者中SGLT2i和GLP1RA的使用均有限。
研究设计与样本
- 研究使用美国国家健康与营养调查(NHANES)、瑞典斯德哥尔摩肌酐测量(SCREAM)项目和以色列Maccabi健康服务的数据库,分析2007至2018年间2型糖尿病的特定药物治疗。
主要发现
- 2017-2018年,2型糖尿病患者中降糖药使用率:NHANES 66.0%,SCREAM 68.4%,Maccabi 88.1%。
- 在2017-2018年至少使用一种降糖药的患者中,二甲双胍使用率:NHANES 74.1%,SCREAM 75.9%,Maccabi 92.6%。
- 磺脲类使用率:NHANES 31.5%,SCREAM 16.0%,Maccabi 14.9%。
- 二肽基肽酶4抑制剂和钠-葡萄糖共转运蛋白2抑制剂(SGLT2i)在NHANES和SCREAM中的采用慢于Maccabi。
- 动脉粥样硬化性心血管疾病、心力衰竭、肾功能减退或白蛋白尿病史与SGLT2i或胰高血糖素样肽1受体激动剂(GLP1RA)使用增加在三个国家中均无一致关联。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To characterize and compare glucose-lowering medication use in type 2 diabetes in the U.S., Sweden, and Israel, including adoption of newer medications and prescribing patterns. RESEARCH DESIGN AND METHODS: We used data from the National Health and Nutrition Examination Survey (NHANES) from the U.S., the Stockholm CREAtinine Measurements (SCREAM) project from Sweden, and Maccabi Healthcare Services (Maccabi) from Israel. Specific pharmacotherapy for type 2 diabetes between 2007 and 2018 was examined. RESULTS: Use of glucose-lowering medications among patients with type 2 diabetes was substantially lower in NHANES and SCREAM than in Maccabi (66.0% in NHANES, 68.4% in SCREAM, and 88.1% in Maccabi in 2017-2018). Among patients who took at least one glucose-lowering medication in 2017-2018, metformin use was also lower in NHANES and SCREAM (74.1% in NHANES, 75.9% in SCREAM, and 92.6% in Maccabi) whereas sulfonylureas use was greater in NHANES (31.5% in NHANES, 16.0% in SCREAM, and 14.9% in Maccabi). Adoption of dipeptidyl peptidase 4 inhibitors and sodium-glucose cotransporter 2 inhibitors (SGLT2i) was slower in NHANES and SCREAM than in Maccabi. History of atherosclerotic cardiovascular disease, heart failure, reduced kidney function, or albuminuria was not consistently associated with greater use of SGLT2i or glucagon-like peptide 1 receptor agonists (GLP1RA) across the three countries. CONCLUSIONS: There were substantial differences in real-world use of glucose-lowering medications across the U.S., Sweden, and Israel, with more optimal pharmacologic management in Israel. Variation in access to care and medication cost across countries may have contributed to these differences. SGLT2i and GLP1RA use in patients at high risk was limited in all three countries during this time period.
引用
- Lyu B, Sang Y, Selvin E, et al. Pharmacologic Treatment of Type 2 Diabetes in the U.S., Sweden, and Israel. Diabetes Care. 2022. PMID: 36282149. doi:10.2337/dc22-1253
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。